COMP <GO>
CTXR vs ALLR // ALTMAN Z-SCORE & DEBT/EQUITY
Citius Pharmaceuticals Inc. (NASDAQ) VS. Allarity Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CTXR 2
— ALLR 1
■ METRIC PARITY
LAST: $0.56 (+4.07%) • MKT CAP: $15.5M
balance-sheet
—
LAST: $0.89 (-6.32%) • MKT CAP: $14.2M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTXR VS. ALLR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTXR | ALLR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | ALLR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 38.9 | +14.80 | CTXR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.5M | $14.2M | $1.3M | CTXR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTXR REV | ALLR REV | CTXR GROSS % | ALLR GROSS % | CTXR FCF | ALLR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$26.6M | -$14.8M |
| FY 2024 | $0 | $0 | — | — | -$28.2M | -$17.6M |
| FY 2023 | $0 | $0 | — | — | -$29.1M | -$12.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTXR // BETA —
ALLR // BETA —